Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

19 trials with published results (34%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

3.6%

2 terminated out of 56 trials

Success Rate

95.7%

+9.2% vs benchmark

Late-Stage Pipeline

41%

23 trials in Phase 3/4

Results Transparency

42%

19 of 45 completed with results

Key Signals

19 with results96% success

Data Visualizations

Phase Distribution

55Total
Not Applicable (5)
Early P 1 (1)
P 1 (10)
P 2 (16)
P 3 (19)
P 4 (4)

Trial Status

Completed45
Unknown5
Recruiting2
Terminated2
Withdrawn1
Not Yet Recruiting1

Trial Success Rate

95.7%

Benchmark: 86.5%

Based on 45 completed trials

Clinical Trials (56)

Showing 20 of 20 trials
NCT07056660Not ApplicableRecruitingPrimary

Atmospheric Pressure Cold Plasma for Moderate-to-severe Tinea Pedis

NCT07245667Phase 2RecruitingPrimary

Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study

NCT04152226Phase 2CompletedPrimary

A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis

NCT06869681Phase 4Not Yet RecruitingPrimary

Efficacy of Tropical Sertaconazole Nitrate 2% Vs Clotrimazole 1% for Tinea Pedis

NCT00233493Completed

Spread of Dermatophytes Among Families

NCT05363449Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

NCT05493488Phase 2UnknownPrimary

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

NCT03129321Phase 3CompletedPrimary

Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis

NCT03897257Phase 2CompletedPrimary

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

NCT00804193Not ApplicableCompletedPrimary

Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea Pedis

NCT00802672Phase 3CompletedPrimary

Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis

NCT04883593Early Phase 1CompletedPrimary

A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

NCT04265521Not ApplicableCompleted

Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet

NCT02842021Phase 2TerminatedPrimary

Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis

NCT04203342Phase 3CompletedPrimary

A Therapeutic Equivalence Study of Ketoconazole Cream 2%

NCT03320486Phase 3CompletedPrimary

Non-inferiority Trial of Dapaconazole Versus Ketoconazole

NCT03676686Not ApplicableCompletedPrimary

Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis

NCT02394340Phase 4CompletedPrimary

Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris

NCT02767271Phase 4CompletedPrimary

Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris

NCT02871011Phase 2CompletedPrimary

Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot

Scroll to load more

Research Network

Activity Timeline